{"filing":{"accession_number":"0001104659-26-088857","cik":"0001737953","ticker":"REPL","company_name":"Replimune Group, Inc.","form":"8-K","filing_date":"2026-07-31","report_date":"2026-07-30","primary_document":"tm2621708d1_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1737953/000110465926088857/tm2621708d1_8k.htm"},"events":[{"id":22744,"run_id":20575,"accession_number":"0001104659-26-088857","anchor_item_number":"8.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"The disclosure announces a favorable FDA Advisory Committee vote (10-3) on the clinical meaningfulness of efficacy data from the IGNYTE study for RP1 in advanced melanoma, with an FDA action date of August 2, 2026. This is a material regulatory milestone in the drug development process that would affect investor assessment of the company's lead product candidate's path to approval, but it does not fit the specific categories of earnings release, M\u0026A activity, restatement, auditor change, going concern, impairment, shareholder vote, delisting, bankruptcy, covenant breach, cybersecurity incident, dilutive issuance, material litigation, debt issuance, dividend distribution, or workforce reduction. It is a significant operational/regulatory development rather than a terminal or governance event.","company_name":"Replimune Group, Inc.","ticker":"REPL","filing_date":"2026-07-31","form":"8-K","submitted_at":null,"items":[{"id":22773,"accession_number":"0001104659-26-088857","item_number":"8.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"The disclosure announces a favorable FDA Advisory Committee vote (10-3) on the clinical meaningfulness of efficacy data from the IGNYTE study for RP1 in advanced melanoma, with an FDA action date of August 2, 2026. This is a material regulatory milestone in the drug development process that would affect investor assessment of the company's lead product candidate's path to approval, but it does not fit the specific categories of earnings release, M\u0026A activity, restatement, auditor change, going concern, impairment, shareholder vote, delisting, bankruptcy, covenant breach, cybersecurity incident, dilutive issuance, material litigation, debt issuance, dividend distribution, or workforce reduction. It is a significant operational/regulatory development rather than a terminal or governance event.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-02T02:22:04.898005+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":22773,"accession_number":"0001104659-26-088857","item_number":"8.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"The disclosure announces a favorable FDA Advisory Committee vote (10-3) on the clinical meaningfulness of efficacy data from the IGNYTE study for RP1 in advanced melanoma, with an FDA action date of August 2, 2026. This is a material regulatory milestone in the drug development process that would affect investor assessment of the company's lead product candidate's path to approval, but it does not fit the specific categories of earnings release, M\u0026A activity, restatement, auditor change, going concern, impairment, shareholder vote, delisting, bankruptcy, covenant breach, cybersecurity incident, dilutive issuance, material litigation, debt issuance, dividend distribution, or workforce reduction. It is a significant operational/regulatory development rather than a terminal or governance event.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-02T02:22:04.898005+00:00","company_name":"Replimune Group, Inc.","ticker":"REPL","filing_date":"2026-07-31"}]}